第一条 为确保山东金城医药集团股份有限公司（以下简称"公司"）重大 交易决策程序规范、有效，依据《中华人民共和国公司法》《中华人民共和国证 券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等法律、法规、规范性文件和《山 东金城医药集团股份有限公司章程》（以下简称"《公司章程》"）的规定，制 定本制度。 山东金城医药集团股份有限公司 重大交易决策制度 山东金城医药集团股份有限公司 重大交易决策制度 第一章 总 则 第二条 公司应当严格遵守有关法律、法规、规范性文件及《公司章程》的 规定，在交易决策中，保障股东会、董事会、总裁办公会各自的权限均得到有效 发挥，做到权责分明，保证公司运作效率。 第三条 公司交易事项中涉及对外投资、提供担保、提供财务资助、关联交 易等事项的具体审议权限划分，按照公司相应制度执行。 第二章 决策范围及程序 第四条 本制度所称"交易"包括下列事项： （一）购买或者出售资产； （二）对外投资（含委托理财、对子公司投资等，设立或者增资全资子公司 除外）； - 1 - （三）提供财务资助（含委托贷款）； （四）提供担保（指公 ...

山东金城医药集团股份有限公司 累积投票制度实施细则 山东金城医药集团股份有限公司 累积投票制实施细则 第一章 总 则 第一条 为了进一步完善山东金城医药集团股份有限公司（以下简称"公司"） 法人治理结构，保证所有股东充分行使权利，根据《中华人民共和国公司法》《中 华人民共和国证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规、 规范性文件及《山东金城医药集团股份有限公司章程》（以下简称"《公司章程》"）， 特制定本实施细则。 第二条 本实施细则所指的累积投票制是指公司股东会选举两个以上董事时， 有表决权的每一股份拥有与拟选出的董事人数相同的表决权，股东拥有的表决权 可以集中使用。 第三条 本实施细则所称董事包括独立董事和非独立董事。 第四条 股东会选举产生的董事人数及结构应符合《公司章程》的规定。 第二章 董事候选人的提名 第五条 公司依照法律、法规和有关规定制定董事候选人提名的方式和程序， 保证选举的公开、公平、公正。 第六条 公司非独立董事候选人、独立董事候选人提名方式和程序为： （一）关于非独立董事和独立董事候选人提名方式 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-059 山东金城医药集团股份有限公司 关于修订《公司章程》及部分制度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）于2025年8月19日召 开第六届董事会第十六次会议，审议通过了《关于修订<公司章程> 及相关议事 规则的议案》《关于修订部分公司治理制度的议案》。公司根据《中华人民共和 国公司法》《上市公司章程指引》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》等法律 法规的相关规定，结合最新监管法规体系和公司实际情况，对《公司章程》及相 关治理制度进行了修订，具体情况如下： 一、《公司章程》修订对照 | 第一条 为维护公司、股东和债权人的合法权 | 第一条 为维护公司、股东、职工和债权人的合法 | | --- | --- | | 益，规范公司的组织和行为，根据《中华人民 | 权益，规范公司的组织和行为，根据《中华人民共 | | 共和国公司法》（以下简称"《公司法》"）、 | 和国公 ...

2025半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：山东金城医药集团股份有限公司 单位：人民币万元 | 非经营性资金 | | 占用方与上市 | 上市公司核算 | 2025年期 | 2025年半年度 占用累计发生 | 2025年半 年度占用 | 2025年半 年度偿还 | 2025年6月 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 占用 | 资金占用方名称 | 公司 | 的会计科目 | 初占用资 | 金额 | 资金的利 | 累计发生 | 末占用资 | 占用形成 原因 | 占用性质 | | | | 的关联关系 | | 金余额 | | | | 金余额 | | | | | | | | | （不含利息） | 息(如有) | 金额 | | | | | 控股股东、实 | | | | | | | | | | | | 际控制人及其 | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-060 山东金城医药集团股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）第六届董事会第十六次会议 审议通过了《关于召开 2025 年第二次临时股东大会的议案》，决定于 2025 年 9 月 8 日召开公司 2025 年第二次临时股东大会，现将有关事项通知如下： 4、会议召开的日期、时间： （1） 现场会议召开时间：2025 年 9 月 8 日（星期一） 下午 2:30 （2） 网络投票时间：2025 年 9 月 8 日（星期一），其中： 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 8 日（星期一） 9:15-9:25，9:30-11:30 和 13:00-15:00。 通过深圳证券交易所互联网系统投票的具体时间为 2025 年 9 月 8 日（星期一） 9:15-15:00 的任意时间。 5、会议的召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 6 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-058 山东金城医药集团股份有限公司 第六届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东金城医药集团股份有限公司第六届监事会第十三次会议于 2025 年 8 月 19 日以现场结合通讯的方式召开。本次监事会会议通知于 2025 年 8 月 8 日以邮 件通知方式发出。本次会议应出席监事 3 人，实际出席监事 3 人。本次监事会会 议由监事会主席李清业先生主持。会议的召开和表决程序符合《公司法》等法律、 法规以及《公司章程》的规定，合法有效。 二、监事会会议审议情况 1、审议通过《关于<2025 年半年度报告全文及其摘要>的议案》 经审核，监事会认为：董事会编制和审核的公司《2025 年半年度报告全文 及其摘要》符合法律、行政法规和中国证监会规定的程序，内容及格式均严格按 照国家财政法规及中国证监会的相关规定进行编制，报告真实、准确、完整地反 映了公司 2025 年上半年的实际经营情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 表决结 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-056 山东金城医药集团股份有限公司 第六届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东金城医药集团股份有限公司第六届董事会第十六次会议通知于 2025 年 8 月 8 日以邮件通知方式发出。本次董事会会议于 2025 年 8 月 19 日在公司会议 室以现场和通讯相结合的方式召开。会议应出席董事 9 名，实际出席会议董事 9 名，其中非独立董事王辉委托非独立董事马钦元出席本次会议，非独立董事张忠 政委托非独立董事崔希礼出席本次会议，独立董事王新宇、蔡启孝、李福利以通 讯方式参与本次会议。 本次会议由董事长赵叶青主持，公司部分监事及高级管理人员列席了会议。 会议的召开和表决程序符合《公司法》等法律法规和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于<2025 年半年度报告全文及其摘要>的议案》。 经公司全体董事审议，一致认为：公司《2025 年半年度报告全文及其摘要》 内容真实、准确、完整地反映了公司 2025 年上半年 ...

Section I Important Notice, Table of Contents, and Definitions [Important Notice](index=2&type=section&id=Important%20Notice) The Board, Supervisory Board, and senior management guarantee report accuracy and completeness, proposing a **CNY 1.00** cash dividend per 10 shares - The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the report's content and assume legal responsibility[5](index=5&type=chunk) - Company head Zhao Yeqing, chief accountant Liu Jing, and head of accounting department Xu Chong declare the financial report is true, accurate, and complete[5](index=5&type=chunk) - Forward-looking statements regarding future plans, development strategies, and business plans in this report do not constitute a substantial commitment to investors, who are advised to be aware of investment risks[5](index=5&type=chunk) 2025 Semi-Annual Profit Distribution Plan | Indicator | Value | | :--- | :--- | | Distribution Base (Shares) | 379,331,587 | | Cash Dividend per 10 Shares (Pre-tax, CNY) | 1.00 | | Bonus Shares | 0 | | Capitalization from Capital Reserve | No | [Catalog of Reference Documents](index=4&type=section&id=Catalog%20of%20Reference%20Documents) Reference documents for the 2025 semi-annual report, including signed financial statements and disclosed files, are available at Jincheng Pharmaceutical's Securities Department - Reference documents include financial statements and the report text signed by the legal representative and chief accountant[10](index=10&type=chunk) - Originals of all company documents and announcements publicly disclosed during the reporting period are also included as reference documents[10](index=10&type=chunk) - The reference documents are available at Jincheng Pharmaceutical Securities Department, No. 1 Shuangshan Road, Zichuan Economic Development Zone, Zibo City, Shandong Province[10](index=10&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines common terms used in the report, such as company names, regulations, subsidiaries, and the reporting period, for clarity - Clarifies that "Company," "the Company," "Pharmaceutical Group," and "Jincheng Pharmaceutical" all refer to Shandong Jincheng Pharmaceutical Group Co., Ltd[11](index=11&type=chunk) - Lists major wholly-owned and controlled subsidiaries, such as Huihai Pharmaceutical, Jincheng Kerui, Jincheng Bio, and Jincheng Taier[11](index=11&type=chunk) - Defines industry-related acronyms such as FDA (U.S. Food and Drug Administration), GMP (Good Manufacturing Practice), and EHS (Environment, Health, Safety)[11](index=11&type=chunk) - The reporting period refers to January 1, 2025, to June 30, 2025[11](index=11&type=chunk) Section II Company Profile and Key Financial Indicators [Company Profile](index=6&type=section&id=I.%20Company%20Profile) The company, Jincheng Pharmaceutical (stock code **300233**), is listed on the Shenzhen Stock Exchange, with Zhao Yeqing as its legal representative - Company stock abbreviation: Jincheng Pharmaceutical, stock code: **300233**[13](index=13&type=chunk) - Stock exchange listed: Shenzhen Stock Exchange[13](index=13&type=chunk) - Company legal representative: Zhao Yeqing[13](index=13&type=chunk) [Contact Persons and Information](index=6&type=section&id=II.%20Contact%20Persons%20and%20Information) The company's Board Secretary is Zhu Xiaogang, investor relations representatives are Ni Yanli and Qi Feng, with disclosed contact details - Board Secretary: Zhu Xiaogang[14](index=14&type=chunk) - Securities Affairs Representatives: Ni Yanli, Qi Feng[14](index=14&type=chunk) - Contact address: No. 1 Shuangshan Road, Zichuan Economic Development Zone, Zibo City, Shandong Province[14](index=14&type=chunk) [Other Information](index=6&type=section&id=III.%20Other%20Information) No changes occurred in the company's contact information, disclosure locations, or registration details during the reporting period - The company's registered address, office address, website, and email address remained unchanged during the reporting period[15](index=15&type=chunk) - Information disclosure and reference locations remained unchanged during the reporting period[16](index=16&type=chunk) - The company's registration status remained unchanged during the reporting period[17](index=17&type=chunk) [Key Accounting Data and Financial Indicators](index=7&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2025, revenue decreased by **22.65%** to **CNY 1.36 billion**, net profit attributable to shareholders fell by **66.78%** to **CNY 43.38 million**, and basic EPS declined to **CNY 0.11/share** 2025 Semi-Annual Key Accounting Data and Financial Indicators | Indicator | Current Reporting Period | Prior Year Same Period | YoY Change in Current Reporting Period | | :--- | :--- | :--- | :--- | | Operating Revenue (CNY) | 1,360,240,655.35 | 1,758,578,253.52 | -22.65% | | Net Profit Attributable to Shareholders (CNY) | 43,383,223.56 | 130,591,570.91 | -66.78% | | Net Profit Attributable to Shareholders Excluding Non-Recurring Gains/Losses (CNY) | 38,730,480.06 | 121,495,520.34 | -68.12% | | Net Cash Flow from Operating Activities (CNY) | 104,367,911.57 | 174,951,312.54 | -40.34% | | Basic Earnings Per Share (CNY/share) | 0.11 | 0.34 | -67.65% | | Diluted Earnings Per Share (CNY/share) | 0.11 | 0.34 | -67.65% | | Weighted Average Return on Net Assets | 1.16% | 3.50% | -2.34% | | Total Assets (CNY) | 5,283,328,116.74 | 5,604,990,741.71 | -5.74% | | Net Assets Attributable to Shareholders (CNY) | 3,697,517,562.34 | 3,766,981,964.99 | -1.84% | [Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=7&type=section&id=V.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20Overseas%20Accounting%20Standards) No differences in net profit and net assets were found between financial reports prepared under international/overseas and Chinese accounting standards during the reporting period - The company's financial reports for the reporting period show no differences in net profit and net assets between International Accounting Standards and Chinese Accounting Standards[19](index=19&type=chunk) - The company's financial reports for the reporting period show no differences in net profit and net assets between overseas accounting standards and Chinese Accounting Standards[20](index=20&type=chunk) [Non-Recurring Gains and Losses Items and Amounts](index=7&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses amounted to **CNY 4.65 million**, primarily from government subsidies, fair value changes, and non-current asset disposals 2025 Semi-Annual Non-Recurring Gains and Losses Items and Amounts | Item | Amount (CNY) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | -308,459.13 | | Government Subsidies Included in Current Period's Gains/Losses | 7,366,340.97 | | Gains/Losses from Changes in Fair Value of Financial Assets and Liabilities Held by Non-Financial Enterprises, and from Disposal of Financial Assets and Liabilities, Excluding Effective Hedge Accounting Related to Normal Business Operations | 753,934.86 | | Other Non-Operating Income and Expenses Apart from the Above | -2,412,714.24 | | Less: Income Tax Impact | 753,695.70 | | Impact on Minority Interests (After Tax) | -7,336.74 | | Total | 4,652,743.50 | - The company has no other gain or loss items that meet the definition of non-recurring gains and losses[23](index=23&type=chunk) - The company has not classified any non-recurring gain or loss items listed in "Interpretive Announcement No. 1 for Information Disclosure by Companies Issuing Securities to the Public—Non-Recurring Gains and Losses" as recurring gain or loss items[23](index=23&type=chunk) Section III Management Discussion and Analysis [Main Business Activities During the Reporting Period](index=9&type=section&id=I.%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) The company operates in pharmaceutical chemicals, synthetic biology, women's health, and anti-infectives, expanding into new tobacco, experiencing revenue and profit declines, but actively enhancing management and R&D [1. Industry Overview During the Reporting Period](index=9&type=section&id=1.%20Industry%20Overview%20During%20the%20Reporting%20Period) The pharmaceutical manufacturing industry, driven by aging populations and health awareness, saw revenue decline by **1.2%** and profit by **2.8%** in H1 2025, prompting innovation and business expansion due to evolving healthcare policies and anti-corruption efforts - From January to June 2025, the pharmaceutical manufacturing industry achieved operating revenue of **CNY 1.22752 trillion**, a year-on-year decrease of **1.2%**[25](index=25&type=chunk) - The pharmaceutical manufacturing industry's total profit was **CNY 176.69 billion**, a year-on-year decrease of **2.8%**[25](index=25&type=chunk) - The state optimized drug centralized procurement policies, strengthened quality assessment and supervision, and continued to combat corruption in pharmaceutical procurement and sales[25](index=25&type=chunk) - Normalized centralized procurement drives pharmaceutical companies to transform and develop through innovation and business expansion[25](index=25&type=chunk) [2. Main Business and Products](index=9&type=section&id=2.%20Main%20Business%20and%20Products) The company strategically focuses on pharmaceutical chemicals, synthetic biology, women's health, high-end anti-infectives, and new tobacco, offering products like cephalosporin side-chain active esters, biopharmaceuticals, specialty APIs, and finished formulations - The company specializes in pharmaceutical chemicals, synthetic biology, women's health technology, and high-end anti-infective fields, expanding into new tobacco[26](index=26&type=chunk) - Key products include cephalosporin side-chain active ester series (e.g., AE active ester, Ceftazidime active ester), biopharmaceuticals, and specialty APIs (e.g., Glutathione, Ademetionine Butanedisulfonate)[26](index=26&type=chunk)[27](index=27&type=chunk) - Finished dosage form products cover multiple areas such as anti-infectives and gynecology/pediatrics, including Nifuratel Nystatin Vaginal Soft Capsules and Cefazolin Sodium for Injection[27](index=27&type=chunk) [3. Operating Model](index=10&type=section&id=3.%20Operating%20Model) The company operates a "strategic headquarters + professional business unit + lean factory" model, with production driven by sales, a diversified sales approach including direct sales and e-commerce, and an R&D system combining in-house development with external collaborations - The company implements a three-tier integrated operating system: "strategic operations headquarters + specialized business units + lean factories"[28](index=28&type=chunk) - The production model generally follows make-to-order, with subsidiaries preparing monthly production plans based on sales forecasts, product inventory, and capacity[28](index=28&type=chunk) - The sales model combines self-operation, dealer recruitment, and OTC for different business segments and product characteristics, primarily focusing on direct sales and self-operated exports in domestic and international markets[28](index=28&type=chunk) - The R&D model relies on national-level enterprise technology centers and provincial key laboratories, combining independent R&D with collaborative R&D to build a balanced "multi-platform" R&D system[29](index=29&type=chunk) [4. Key Initiatives During the Reporting Period](index=10&type=section&id=4.%20Key%20Initiatives%20During%20the%20Reporting%20Period) In H1 2025, the company's revenue decreased by **22.65%** to **CNY 1.36 billion** and net profit by **66.78%** to **CNY 43.38 million** due to market competition, despite stable biopharmaceutical operations, while enhancing management, digital marketing, production, and R&D, securing new drug registrations and international certifications - During the reporting period, the company's biopharmaceutical business remained stable, but market competition for cephalosporin side-chain pharmaceutical intermediates and cephalosporin powder injections intensified, leading to decreased sales volume and prices[30](index=30&type=chunk)[31](index=31&type=chunk) 2025 Semi-Annual Operating Performance | Indicator | Amount (CNY 100 Million) | YoY Change | | :--- | :--- | :--- | | Operating Revenue | 13.60 | -22.65% | | Net Profit Attributable to Shareholders | 0.4338 | -66.78% | - The company continued to improve its "strategic management headquarters + specialized business unit + lean factory" organizational structure and signed a product introduction agreement with UK women's health technology brand Theramex[31](index=31&type=chunk) - The marketing center continued to build a digital marketing platform, Jincheng Taier actively participated in centralized procurement, and sales of Glutathione and Ademetionine increased year-on-year[31](index=31&type=chunk)[32](index=32&type=chunk) - The company strengthened quality management to benchmark international standards, established a DMF quality management system, and achieved zero safety production accidents and zero environmental management complaints[32](index=32&type=chunk) - R&D management capabilities improved, with 3 products including Bisoprolol Fumarate and Posaconazole Enteric-coated Tablets obtaining drug registration certificates, and Posaconazole API receiving an FA Letter from the US FDA[33](index=33&type=chunk)[34](index=34&type=chunk) - The company deeply implemented "risk, internal control, and compliance integration" work, enhancing risk prevention and control capabilities and trade secret protection levels[34](index=34&type=chunk) [5. Local Centralized Procurement Bidding Results During the Reporting Period](index=12&type=section&id=5.%20Local%20Centralized%20Procurement%20Bidding%20Results%20During%20the%20Reporting%20Period) No new national centralized procurement bids were won, but Lornoxicam for Injection and Nifuratel Capsules were newly selected in local bids (not yet executed), while Nifuratel Nystatin Vaginal Soft Capsules and Nabumetone Dispersible Tablets had actual procurement volumes - The company's products had no new successful bids in national centralized procurement[36](index=36&type=chunk) - Lornoxicam for Injection and Nifuratel Capsules were newly selected in local centralized procurement, but have not yet been executed[36](index=36&type=chunk) H1 2025 Local Centralized Procurement Key Product Procurement Volume | Drug Name | Specification | Price (CNY/bottle/capsule/tablet) | Company Name | H1 2025 Total Actual Procurement Volume by Medical Institutions (Ten Thousand bottles/capsules/tablets) | | :--- | :--- | :--- | :--- | :--- | | Nifuratel Nystatin Vaginal Soft Capsules | Nifuratel 0.5g, Nystatin 200,000 units*6 capsules/box | 3.45 | Jincheng Taier | 31.5 | | Nifuratel Nystatin Vaginal Soft Capsules | Nifuratel 0.5g, Nystatin 200,000 units*12 capsules/box | 3.45 | Jincheng Taier | 101.52 | | Nifuratel Nystatin Vaginal Soft Capsules | Nifuratel 0.5g, Nystatin 200,000 units*6 capsules/box | 2.99 | Jincheng Taier | 0.9 | | Nifuratel Nystatin Vaginal Soft Capsules | Nifuratel 0.5g, Nystatin 200,000 units*12 capsules/box | 2.99 | Jincheng Taier | 194.184 | | Nabumetone Dispersible Tablets | 0.5g*8 tablets/box | 4.14 | Jincheng Taier | 9.76 | | Levofloxacin Tablets | 0.5g*18 tablets/box 0.25g*30 tablets/box | 0.79、0.46 | Jincheng Suzhi | 12.6 | [6. Drug Registration Application Status During the Reporting Period](index=12&type=section&id=6.%20Drug%20Registration%20Application%20Status%20During%20the%20Reporting%20Period) **8 products**, including Cefotaxime Sodium for Injection and Posaconazole Enteric-coated Tablets, received drug registration certificates, Posaconazole API obtained US FDA approval, and Erythromycin Lactobionate API was approved in August 2025, with other products under review or supplementary research - **8 products**, including Cefotaxime Sodium for Injection, Cefazolin Sodium for Injection, Bisoprolol Fumarate, and Posaconazole Enteric-coated Tablets, have obtained drug registration certificates[35](index=35&type=chunk)[37](index=37&type=chunk) - Posaconazole API received an FA Letter from the US FDA, and Erythromycin Lactobionate API was approved in August 2025[37](index=37&type=chunk) - Minocycline Hydrochloride for Injection obtained clinical trial approval, and several products including Ademetionine Butanedisulfonate Enteric-coated Tablets, Glutathione, and Ademetionine Butanedisulfonate are under review or supplementary research, with active overseas registration efforts[37](index=37&type=chunk)[38](index=38&type=chunk) [7. Patents Applied For During the Reporting Period](index=14&type=section&id=7.%20Patents%20Applied%20For%20During%20the%20Reporting%20Period) During the reporting period, the company applied for **16 patents**, including invention and utility model patents, covering pharmaceutical preparation methods, enzyme mutants, environmental equipment, detection methods, continuous production devices, and lyophilization processes, demonstrating continuous innovation in pharmaceutical chemicals and biotechnology - The company applied for a total of **16 patents**, including invention patents and utility model patents[39](index=39&type=chunk) - Patent content covers Cefadroxil capsule preparation, imine reductase mutants, hazardous waste incinerators, HPLC detection methods, carbapenem intermediate production devices, and Erythromycin Lactobionate lyophilization processes[39](index=39&type=chunk) [8. Patents Granted During the Reporting Period](index=15&type=section&id=8.%20Patents%20Granted%20During%20the%20Reporting%20Period) During the reporting period, **4 invention patents** were granted, including methods for producing astaxanthin using *Yarrowia lipolytica*, curcumin/dihydrocurcumin reductase mutants, ceftazidime side-chain acid ethyl ester synthesis, and continuous production of carbapenem intermediate 4-AA - The company had **4 invention patents** approved[40](index=40&type=chunk) - Approved patents include "A method for engineered *Yarrowia lipolytica* to produce astaxanthin" and "Continuous production device and method for carbapenem intermediate 4-AA" etc[40](index=40&type=chunk) [9. Changes in National Medical Insurance Drug Catalog During the Reporting Period](index=15&type=section&id=9.%20Changes%20in%20National%20Medical%20Insurance%20Drug%20Catalog%20During%20the%20Reporting%20Period) During the reporting period, there were no changes in the inclusion or exclusion of the company's products from the National Medical Insurance Drug Catalog - During the reporting period, there were no changes in the inclusion or exclusion of the company's products from the National Medical Insurance Drug Catalog[41](index=41&type=chunk) [Analysis of Core Competencies](index=15&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core competencies span R&D, industrial scale, production operations, safety and environmental protection, and brand culture, featuring national-level R&D platforms, leading market shares in key products, robust manufacturing, and a strong brand reputation [1. Technological R&D Advantages](index=15&type=section&id=1.%20Technological%20R%26D%20Advantages) The company leverages national-level R&D platforms and a three-tier innovation system, excelling in chemical synthesis of cephalosporin intermediates and carbapenem nuclei, and possessing nearly a hundred advanced synthetic biology technologies, including continuous flow reactions and enzyme-catalyzed chiral synthesis - The company possesses national-level enterprise technology centers, postdoctoral research workstations, and other R&D platforms, establishing a three-tier R&D innovation system encompassing independent innovation, collaborative innovation, and investment innovation[41](index=41&type=chunk) - In chemical synthesis, it has built a pharmaceutical chemical industry system primarily focused on cephalosporin pharmaceutical intermediates, carbapenem nuclei, specialty APIs, and new tobacco products[42](index=42&type=chunk) - Possesses nearly a hundred advantageous technologies, including continuous flow reaction technology, "chiral synthesis, anhydrous and anaerobic conditions, deep cryogenic high pressure, directed evolution of enzymes, cell factory construction, and fermentation metabolic regulation" etc[42](index=42&type=chunk) [2. Industrial and Scale Advantages](index=16&type=section&id=2.%20Industrial%20and%20Scale%20Advantages) The company, deeply rooted in pharmaceutical manufacturing and health industries, has a diversified business centered on cephalosporin intermediates and biopharmaceutical APIs, holding leading domestic market shares in these areas, supported by nine modern production bases with integrated manufacturing capabilities ensuring stable quality, controlled costs, and increased market share - The company has formed a diversified business system centered on cephalosporin pharmaceutical intermediates, biopharmaceuticals, and specialty APIs[42](index=42&type=chunk) - Domestic market share for cephalosporin pharmaceutical intermediates and Glutathione API consistently ranks among the top in the industry[42](index=42&type=chunk) - Nine modern production bases have been established, possessing integrated production capabilities for intermediates, APIs, and finished formulations[42](index=42&type=chunk) [3. Production and Operation Advantages](index=16&type=section&id=3.%20Production%20and%20Operation%20Advantages) The company continuously advances GMP, lean management, and EHS compliance, strengthening sales-centric operations and new productivity, boasting robust manufacturing and supply chain capabilities, supported by an experienced team with extensive expertise across product development, production, quality control, and sales - The company continuously promotes GMP, lean management, and EHS compliance, drives the development of new quality productive forces, and possesses strong manufacturing and supply chain assurance capabilities[43](index=43&type=chunk) - Possesses a highly professional and experienced management team, along with a skilled, cohesive, efficient, and stable workforce[43](index=43&type=chunk) - Has accumulated rich practical experience in product R&D, customization, production, testing, quality control, and sales[43](index=43&type=chunk) [4. Safety and Environmental Protection Advantages](index=16&type=section&id=4.%20Safety%20and%20Environmental%20Protection%20Advantages) The company prioritizes safety, production, and environmental protection, enhancing automation and intelligence for standardized safety management and smart risk warnings, upgrading equipment to reduce personnel, and achieving green development through source reduction, process control, end-of-pipe treatment, and comprehensive utilization, with multiple subsidiaries recognized as national green factories - The company strengthens automation and intelligent transformation, achieving standardization and informatization of safety production management, as well as intelligent personnel positioning and smart risk early warning[43](index=43&type=chunk) - Achieves a green development mechanism of resource conservation, cost reduction, and efficiency improvement through source reduction, process control, end-of-pipe treatment, and comprehensive utilization[43](index=43&type=chunk) - Upgrades and transforms wastewater biochemical treatment systems, RTO exhaust gas treatment devices, etc., enhancing "three wastes" treatment capabilities, with multiple subsidiaries awarded national green factory titles[43](index=43&type=chunk) [5. Brand and Culture Advantages](index=17&type=section&id=5.%20Brand%20and%20Culture%20Advantages) The company highly values brand and culture, promoting integrity, building a systematic corporate culture, establishing a "quick response, precise service" customer system, fostering long-term strategic partnerships with leading pharmaceutical companies, and developing comprehensive training and career paths to enhance employee cohesion and create tripartite value - The company highly values corporate and product brand building, advocates integrity in business operations, and has established a systematic corporate culture framework[44](index=44&type=chunk) - Has established a "quick response, precise service" customer service system and built long-term, stable strategic cooperative relationships with numerous excellent pharmaceutical companies[44](index=44&type=chunk) - Has established a comprehensive training system and career development channels, providing employees with broad development platforms and enhancing employee cohesion[44](index=44&type=chunk) [Analysis of Main Business](index=17&type=section&id=III.%20Analysis%20of%20Main%20Business) During the reporting period, main business revenue decreased by **22.65%** due to reduced marketing expenses and lower exchange gains, with declining revenue and gross margins for most product lines, except for biopharmaceuticals and specialty APIs, which grew by **10.12%** [1. Year-on-Year Changes in Key Financial Data](index=17&type=section&id=1.%20Year-on-Year%20Changes%20in%20Key%20Financial%20Data) During the reporting period, operating revenue decreased by **22.65%**, sales expenses fell by **42.33%**, financial expenses increased by **152.58%** due to lower exchange gains, net operating cash flow decreased by **40.34%**, and net financing cash flow declined by **193.42%** due to bank loan repayments 2025 Semi-Annual Year-on-Year Changes in Key Financial Data | Indicator | Current Reporting Period (CNY) | Prior Year Same Period (CNY) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 1,360,240,655.35 | 1,758,578,253.52 | -22.65% | | | Operating Cost | 868,771,753.18 | 1,044,273,476.63 | -16.81% | | | Selling Expenses | 160,343,056.86 | 278,049,225.02 | -42.33% | Primarily due to reduced market promotion and maintenance fees during the reporting period | | Financial Expenses | 1,049,619.83 | -1,996,378.83 | 152.58% | Primarily due to reduced exchange gains during the reporting period | | Net Cash Flow from Operating Activities | 104,367,911.57 | 174,951,312.54 | -40.34% | Primarily due to decreased acceptance collection and reduced cash receipts from lower revenue during the reporting period | | Net Cash Flow from Financing Activities | -263,541,230.81 | -89,816,089.74 | -193.42% | Primarily due to bank loan repayments during the reporting period | | Net Increase in Cash and Cash Equivalents | -184,326,987.06 | 65,284,463.89 | -382.34% | Primarily due to the combined impact of financing, operating, and investing activities | - The company's profit structure or sources of profit did not undergo significant changes during the reporting period[46](index=46&type=chunk) [2. Products or Services Accounting for Over 10% of Revenue](index=17&type=section&id=2.%20Products%20or%20Services%20Accounting%20for%20Over%2010%25%20of%20Revenue) Revenue from cephalosporin side-chain active esters, finished formulations, and other pharmaceutical chemicals declined with reduced gross margins, while biopharmaceuticals and specialty APIs saw a **10.12%** revenue increase despite a **5.41%** gross margin decrease 2025 Semi-Annual Key Products or Services Overview | Product or Service | Operating Revenue | Operating Cost | Gross Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Cephalosporin Side-Chain Active Ester Series Products | 297,598,253.09 | 208,729,497.07 | 29.86% | -32.20% | -27.73% | -4.35% | | Biopharmaceuticals and Specialty API Series Products | 230,198,218.45 | 124,336,244.48 | 45.99% | 10.12% | 22.38% | -5.41% | | Finished Formulation Products | 470,458,142.79 | 234,326,679.06 | 50.19% | -29.04% | -18.24% | -6.59% | | Other Pharmaceutical Chemical Products | 361,986,041.02 | 301,379,332.57 | 16.74% | -19.12% | -17.94% | -1.20% | [Analysis of Non-Core Business](index=18&type=section&id=IV.%20Analysis%20of%20Non-Core%20Business) During the reporting period, the company had no non-core business analysis - The company had no non-core business analysis during the reporting period[48](index=48&type=chunk) [Analysis of Assets and Liabilities](index=18&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) At the end of the reporting period, total assets decreased by **5.74%**, and net assets attributable to shareholders by **1.84%**, with declines in cash, accounts receivable, and long-term borrowings, but increases in short-term borrowings, construction in progress, and inventory; fair value financial assets totaled **CNY 281 million**, financial liabilities **CNY 36,800**, and some assets were restricted [1. Significant Changes in Asset Composition](index=18&type=section&id=1.%20Significant%20Changes%20in%20Asset%20Composition) At the end of the reporting period, total assets were **CNY 5.283 billion**, a **5.74%** decrease from the prior year-end, with declines in cash, accounts receivable, and long-term borrowings, but increases in short-term borrowings, construction in progress, and inventory 2025 Semi-Annual Changes in Asset Composition | Item | Amount at End of Current Reporting Period (CNY) | Percentage of Total Assets | Amount at Prior Year-End (CNY) | Percentage of Total Assets | Change in Proportion | | :--- | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 753,869,136.82 | 14.27% | 917,670,953.09 | 16.37% | -2.10% | | Accounts Receivable | 439,242,781.79 | 8.31% | 570,531,842.57 | 10.18% | -1.87% | | Inventories | 605,789,334.94 | 11.47% | 598,863,558.41 | 10.68% | 0.79% | | Fixed Assets | 2,142,456,505.74 | 40.55% | 2,228,579,550.89 | 39.76% | 0.79% | | Construction in Progress | 116,208,742.07 | 2.20% | 73,332,415.73 | 1.31% | 0.89% | | Short-term Borrowings | 114,070,413.90 | 2.16% | 55,039,277.50 | 0.98% | 1.18% | | Long-term Borrowings | 246,393,048.92 | 4.66% | 351,994,368.71 | 6.28% | -1.62% | [2. Major Overseas Assets](index=18&type=section&id=2.%20Major%20Overseas%20Assets) During the reporting period, the company had no major overseas assets - The company had no major overseas assets during the reporting period[50](index=50&type=chunk) [3. Assets and Liabilities Measured at Fair Value](index=18&type=section&id=3.%20Assets%20and%20Liabilities%20Measured%20at%20Fair%20Value) At the end of the reporting period, financial assets measured at fair value totaled **CNY 280.92 million**, primarily other equity instrument investments and accounts receivable financing, while financial liabilities totaled **CNY 36,821.31**, with "other changes" in accounts receivable financing due to bank acceptance bills received from sales 2025 Semi-Annual Assets and Liabilities Measured at Fair Value | Item | Beginning Balance (CNY) | Fair Value Change Gains/Losses for Current Period (CNY) | Accumulated Fair Value Changes Recognized in Equity (CNY) | Amount Purchased in Current Period (CNY) | Amount Sold in Current Period (CNY) | Other Changes (CNY) | Ending Balance (CNY) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **Financial Assets** | | | | | | | | | Financial Assets Held for Trading | | | | 490,000,000.00 | 490,000,000.00 | | | | Derivative Financial Assets | 107,044.84 | 106,455.71 | | | 213,500.55 | | 0.00 | | Other Equity Instrument Investments | 164,611,500.47 | | 69,774,000.47 | | | | 162,511,500.47 | | Accounts Receivable Financing | 105,029,422.47 | | | | | 13,382,090.79 | 118,411,513.26 | | **Total Above** | 269,747,967.78 | 106,455.71 | 69,774,000.47 | 490,000,000.00 | 490,213,500.55 | 13,382,090.79 | 280,923,013.73 | | **Financial Liabilities** | 0.00 | 36,821.31 | | | | | 36,821.31 | - "Other changes" in accounts receivable financing are due to bank acceptance bills received from sales of goods and services during the reporting period[52](index=52&type=chunk) - The measurement attributes of the company's major assets did not undergo significant changes during the reporting period[53](index=53&type=chunk) [4. Asset Restrictions as of the End of the Reporting Period](index=19&type=section&id=4.%20Asset%20Restrictions%20as%20of%20the%20End%20of%20the%20Reporting%20Period) As of the end of the reporting period, details of restricted assets are provided in Financial Report Note VII, Consolidated Financial Statement Items Annotation 20, Assets with Restricted Ownership or Use Rights - Details of asset restrictions are provided in Section VIII Financial Report, VII. Consolidated Financial Statement Items Annotation 20, Assets with Restricted Ownership or Use Rights[53](index=53&type=chunk) [Analysis of Investment Status](index=19&type=section&id=VI.%20Analysis%20of%20Investment%20Status) During the reporting period, investments surged by **1253.89%** to **CNY 101 million**, with no major equity or non-equity investments; fair value financial assets totaled **CNY 163 million**; entrusted wealth management amounted to **CNY 490 million**, and hedging derivative investments, with **USD 1.32 million** in forward foreign exchange contracts, resulted in a **CNY -143,900** fair value change, effectively mitigating exchange rate risk [1. Overall Situation](index=19&type=section&id=1.%20Overall%20Situation) During the reporting period, the company's investment amounted to **CNY 101 million**, representing a **1253.89%** increase compared to the same period last year Investment Amount During the Reporting Period | Indicator | Amount (CNY) | | :--- | :--- | | Investment Amount in Current Reporting Period | 101,000,000.00 | | Investment Amount in Prior Year Same Period | 7,460,000.00 | | Change Percentage | 1,253.89% | [2. Significant Equity Investments Acquired During the Reporting Period](index=19&type=section&id=2.%20Significant%20Equity%20Investments%20Acquired%20During%20the%20Reporting%20Period) During the reporting period, the company had no significant equity investments - The company had no significant equity investments during the reporting period[55](index=55&type=chunk) [3. Significant Non-Equity Investments in Progress During the Reporting Period](index=19&type=section&id=3.%20Significant%20Non-Equity%20Investments%20in%20Progress%20During%20the%20Reporting%20Period) During the reporting period, the company had no significant non-equity investments - The company had no significant non-equity investments during the reporting period[55](index=55&type=chunk) [4. Financial Assets Measured at Fair Value](index=19&type=section&id=4.%20Financial%20Assets%20Measured%20at%20Fair%20Value) At the end of the reporting period, financial assets measured at fair value totaled **CNY 162.51 million**, primarily comprising funds and other financial derivatives, with a fair value change loss of **CNY 1.99 million** for the current period 2025 Semi-Annual Financial Assets Measured at Fair Value | Item | Cost (CNY) | Value Change Gains/Losses (CNY) | Accumulated Fair Value Changes Recognized in Equity (CNY) | Amount Purchased (CNY) | Amount Sold (CNY) | Gains (CNY) | Ending Balance (CNY) | Source of Funds | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Funds | 20,000,000.00 | | 14,338,973.59 | | | | 34,338,973.59 | Own Funds | | Other | 72,737,500.00 | -2,100,000.00 | 55,435,026.88 | | | 4,425,362.89 | 128,172,526.88 | Own Funds | | Financial Derivatives | | 106,455.71 | | | 213,500.55 | 213,500.55 | 0.00 | Own Funds | | Other | | | | 490,000,000.00 | 490,000,000.00 | 552,880.31 | | Own Funds | | Total | 92,737,500.00 | -1,993,544.29 | 69,774,000.47 | 490,000,000.00 | 490,213,500.55 | 5,191,743.75 | 162,511,500.47 | -- | [5. Use of Raised Funds](index=20&type=section&id=5.%20Use%20of%20Raised%20Funds) During the reporting period, the company had no use of raised funds - The company had no use of raised funds during the reporting period[58](index=58&type=chunk) [6. Entrusted Wealth Management, Derivative Investments, and Entrusted Loans](index=20&type=section&id=6.%20Entrusted%20Wealth%20Management%2C%20Derivative%20Investments%2C%20and%20Entrusted%20Loans) During the reporting period, entrusted wealth management amounted to **CNY 490 million** with no outstanding balance; hedging derivative investments included **USD 1.32 million** in forward foreign exchange contracts, resulting in a **CNY -143,900** fair value change, effectively mitigating exchange rate risk, and no entrusted loans were present 2025 Semi-Annual Entrusted Wealth Management Overview | Specific Type | Source of Entrusted Wealth Management Funds | Amount of Entrusted Wealth Management (CNY Ten Thousand) | Outstanding Balance (CNY Ten Thousand) | Overdue Unrecovered Amount (CNY Ten Thousand) | | :--- | :--- | :--- | :--- | :--- | | Bank Wealth Management Products | Own Funds | 49,000 | 0 | 0 | | Total | | 49,000 | 0 | 0 | - The company had no significant, low-safety, or illiquid high-risk entrusted wealth management products during the reporting period, nor any situations where principal was expected to be unrecoverable or impaired[60](index=60&type=chunk) 2025 Semi-Annual Derivative Investments for Hedging Purposes | Derivative Investment Type | Initial Investment Amount (CNY Ten Thousand) | Beginning Balance (CNY Ten Thousand) | Fair Value Change Gains/Losses for Current Period (CNY Ten Thousand) | Amount Purchased During Reporting Period (CNY Ten Thousand) | Amount Sold During Reporting Period (CNY Ten Thousand) | Ending Balance (CNY Ten Thousand) | Proportion of Ending Investment Amount to Company's Net Assets at Reporting Period End | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |

证券代码：300233 证券简称：金城医药 公告编号：2025-057 山东金城医药集团股份有限公司 二、利润分配方案的合理性说明 本次利润分配方案符合《公司法》《上市公司监管指引第3号--上市公司现 金分红》《深圳证券交易所上市公司自律监管指引第2号--创业板上市公司规范 运作》及《公司章程》等有关规定，与公司实际情况相匹配，充分考虑了对广大 投资者的合理投资回报，有利于全体股东共享公司成长的经营成果；实施本方案 不会造成公司流动资金短缺或者其他不利影响。 2025 年半年度利润分配方案 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）于2025年8月19日召 开第六届董事会第十六次会议和第六届监事会第十三次会议，分别审议通过 《2025年半年度利润分配方案》，现将有关情况公告如下： 一、公司利润分配方案的基本情况 根据公司 2025 年半年度未经审计的财务报告，截止 2025 年 6 月 30 日，公 司合并报表可供股东分配的利润为 834,426,708.43 元，母公司可供股东分配的 利润为 353,58 ...

Market Overview - As of 13:59, the Shanghai Composite Index is at 3723.60 points, with a decline of 0.12% [1] - The total trading volume of A-shares today is 21,733.08 billion yuan [1] Moving Average Analysis - 26 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Yangzi New Materials: 5-day MA is 1.11% lower than the 10-day MA [1] - Ningbo Fanzheng: 5-day MA is 0.94% lower than the 10-day MA [1] - China Petroleum: 5-day MA is 0.40% lower than the 10-day MA [1] Individual Stock Performance - Yangzi New Materials (002652): Today's change is +0.52%, with a 5-day MA of 3.91 yuan and a 10-day MA of 3.95 yuan, showing a distance of -1.11% [1] - Ningbo Fanzheng (300998): Today's change is -1.59%, with a 5-day MA of 25.04 yuan and a 10-day MA of 25.28 yuan, showing a distance of -0.94% [1] - China Petroleum (601857): Today's change is -0.58%, with a 5-day MA of 8.62 yuan and a 10-day MA of 8.66 yuan, showing a distance of -0.40% [1] Additional Stock Insights - Huabei Pharmaceutical (600812): No change today, with a 5-day MA of 6.67 yuan and a 10-day MA of 6.69 yuan, showing a distance of -0.28% [1] - ST Modern (002656): No change today, with a 5-day MA of 2.27 yuan and a 10-day MA of 2.28 yuan, showing a distance of -0.26% [1] - TBEA (600089): Today's change is -0.81%, with a 5-day MA of 13.52 yuan and a 10-day MA of 13.55 yuan, showing a distance of -0.24% [1]